Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07037836 · ClinicalTrials.gov registry record · Phase 2

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

A Phase 2 study of Hypoxemia and COPD (Chronic Obstructive Pulmonary Disease), sponsored by Bastiaan Driehuys.

Recruiting
Registry status
Phase 2
Development phase
10
Enrollment target
1
Study location

NCT07037836 is a Phase 2 study of Hypoxemia and COPD (Chronic Obstructive Pulmonary Disease) that is actively recruiting participants, run by Bastiaan Driehuys. The registered enrollment target is 10 participants, below the 495-participant average among 10 other Hypoxemia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07037836, a Phase 2 study of Hypoxemia and COPD (Chronic Obstructive Pulmonary Disease), is actively recruiting participants, sponsored by Bastiaan Driehuys.

RECRUITING
Registry status
Phase 2
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to evaluate whether inhaled Treprostinil (Tyvaso) can improve oxygen delivery and blood flow in the lungs in adults (age ≥40) with chronic obstructive pulmonary disease (COPD) and hypoxemia who have less severe reduction in lung blood volume (diffusing capacity of the lungs for carbon monoxide \[DLCO\] ≥45%). The main questions it aims to answer are: 1. Does inhaled Treprostinil increase pulmonary capillary blood volume in ventilated lung regions, as measured by hyperpolarized xenon-129 magnetic resonance imaging (HP129Xe MRI)? 2. Does inhaled Treprostinil improve oxygen delivery (measured as red blood cell \[RBC\] chemical shift) and maintain or only slightly change pulmonary vascular resistance (measured by RBC oscillation amplitude)? 3. Can pre-treatment MRI parameters (RBC transfer and RBC oscillation amplitude) predict who will respond to inhaled Treprostinil? Participants will: * Use the Tyvaso nebulizer (inhaled Treprostinil) 4 times daily for 4 weeks, starting at 3 breaths per session and increasing to a maximum of 6 breaths per session as tolerated. * Undergo HP129Xe MRI before and after treatment to assess regional lung function and oxygen exchange. * Complete pulmonary function tests (PFTs), 6-minute walk tests (6MWT), and echocardiograms at the beginning and end of the study. * Be monitored for adverse events, with a phone check-in midway through and after the treatment period.

Conditions Studied

Hypoxemia COPD (Chronic Obstructive Pulmonary Disease)

Interventions

  • DRUG Inhaled Treprostinil (Tyvaso Nebulizer)

Study Locations (1)

North Carolina

  • Duke Asthma Allergy and Airway Center - Durham

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2025-09-29
Est. Completion 2027-07-01
Phase Phase 2

Sponsor

Bastiaan Driehuys

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07037836

The ClinicalTrials.gov registry entry for NCT07037836 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 495-participant average among 10 other Hypoxemia trials with a reported enrollment target (98% lower). The listed sponsor is Bastiaan Driehuys, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hypoxemia appearing as the primary indexed condition, and to 1 intervention - of which Inhaled Treprostinil (Tyvaso Nebulizer) is the first listed.

NCT07037836 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT07037836 about?

NCT07037836 is a clinical study titled "Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia". The goal of this clinical trial is to evaluate whether inhaled Treprostinil (Tyvaso) can improve oxygen delivery and blood flow in the lungs in adults (age ≥40) with chronic obstructive pulmonary disease (COPD) and hypoxemia who have less severe reduction in lung blood volume (diffusing capacity of ...

What is the current status of trial NCT07037836?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-09-29. Estimated completion is 2027-07-01.

What conditions does trial NCT07037836 study?

This clinical trial studies the following conditions: Hypoxemia, COPD (Chronic Obstructive Pulmonary Disease).

What interventions are being tested in trial NCT07037836?

The interventions under investigation include: Inhaled Treprostinil (Tyvaso Nebulizer) (DRUG).

Who is sponsoring clinical trial NCT07037836?

This trial is sponsored by Bastiaan Driehuys, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07037836 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypoxemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypoxemia

All registered trials for this condition

COPD (Chronic Obstructive Pulmonary Disease)

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.